Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Osteosarcoma 2Myelodysplastic Syndromes 2Lymphoma, Follicular 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Renal Insufficiency, Chronic 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Ovarian Neoplasms 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1Lung Neoplasms 1

Interventions

TAK-243 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Anemia, Refractory, with Excess of Blasts × Specimen Handling × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡